Prognosis of Patients With Early Breast Cancer Receiving 5 Years vs 2 Years of Adjuvant Bisphosphonate Treatment: A Phase 3 Randomized Clinical Trial

IMPORTANCE: Bisphosphonate treatment in patients with early breast cancer has become part of care, but the optimal treatment duration is still unclear. OBJECTIVE: To compare 2 vs 5 years of zoledronate treatment following adjuvant chemotherapy in patients with early breast cancer. DESIGN, SETTING, A...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:JAMA Oncol
Glavni autori: Friedl, Thomas W. P., Fehm, Tanja, Müller, Volkmar, Lichtenegger, Werner, Blohmer, Jens, Lorenz, Ralf, Forstbauer, Helmut, Fink, Visnja, Bekes, Inga, Huober, Jens, Jückstock, Julia, Schneeweiss, Andreas, Tesch, Hans, Mahner, Sven, Brucker, Sara Y., Heinrich, Georg, Häberle, Lothar, Fasching, Peter A., Beckmann, Matthias W., Coleman, Robert E., Janni, Wolfgang, Rack, Brigitte
Format: Artigo
Jezik:Inglês
Izdano: American Medical Association 2021
Teme:
Original Investigation
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8227465/
https://ncbi.nlm.nih.gov/pubmed/34165508
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2021.1854
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items